Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft

• Published in: Experimental and molecular pathology 2005-08, Vol.79 (1), p.23-32
• Main Authors: Glasscock, Laura N., Réhault, Sophie M., Gregory, Christopher W., Cooper, Scott T., Jackson, Tracy P., Hoffman, Maureane, Church, Frank C.
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Biomarkers, Tumor - analysis; Blotting, Northern; Cell Line, Tumor; Human kallikreins; Humans; Immunohistochemistry; In Situ Hybridization; Investigative techniques, diagnostic techniques (general aspects); Male; Medical sciences; Mice; Mice, Nude; Neoplasm Transplantation; Nephrology. Urinary tract diseases; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Prostate; Prostatic carcinoma; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Protein C Inhibitor - biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Serpin; Transplantation, Heterologous; Tumors of the urinary system; Urinary tract. Prostate gland
• ISSN: 0014-4800; 1096-0945
• DOI: 10.1016/j.yexmp.2005.02.008

The serine protease inhibitor (serpin) protein C inhibitor (PCI) has been found in the prostate and possibly is a marker to distinguish normal prostate, benign prostatic hyperplasia, and prostate cancer. In this study, we assessed PCI expression in normal, hyperplastic, and malignant prostatic tissues, prostate cancer cell lines, and the CWR22 prostate cancer xenograft model that allowed us to study PCI expression and its regulation in response to androgens. By Northern blot, immunohistochemistry, and in situ hybridization, we found that PCI was expressed in both benign and malignant prostate tissues. Protein C inhibitor was expressed in both androgen-independent (PC-3) and androgen-dependent (LNCaP) prostate cancer cell lines. Furthermore, PCI was detected in all CWR22 tumor samples (androgen dependent, 6 days post-castration, 12 days post-castration followed by 72 h of testosterone treatment, and recurrent CWR22 tumor), although expression of the mature forms of both prostate-specific antigen (PSA) and its homolog, kallikrein 2 (hK2), was clearly androgen-dependent. These results suggest that PCI expression is not regulated by androgens and that PCI is unlikely to be a tumor suppressor gene, but also that PCI may be involved in regulating key serine proteases involved in metastatic prostate disease.